AAP Releases RSV Prevention, COVID Vax Recommendations for Fall

The American Academy of Pediatrics (AAP) issued updated recommendations on the prevention of respiratory syncytial virus (RSV) and the use of COVID vaccines. The AAP Committee on Infectious Diseases recommends all infants younger than 8 months who are born during or entering their first RSV season be immunized, unless they have documented protection from maternal vaccination. The committee also recommends RSV immunization for those ages 8 to 19 months who are at high risk of severe RSV disease and entering their second RSV season.

The AAP Committee on Infectious Diseases recommends that all infants and children ages 6 to 23 months with no contraindications receive the 2026-2027 COVID vaccine. In addition, children and adolescents ages 6 months to 18 years who are moderately or severely immunocompromised should receive two or more doses of an age-appropriate vaccine, depending on previous vaccination status. Finally, children and adolescents 2 years and up who are not considered at increased risk of severe COVID should be offered a single dose of an age-appropriate COVID vaccine if their parent or guardian wants their child to be protected against COVID.

Learn more about AAP’s recommendations for the prevention of RSV here and the use of COVID vaccines here.